Dramatism and Musical Theater

Beasley, Kimberly Eckel; Beasley, James P.

doi:10.3726/b17556

Cited by 2 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…4, No. 4,1985 Our study was carried out on a considerable number of infants at risk of infection and confirms some data that have already appeared in the literature:…”

Section: Discussionsupporting

confidence: 88%

“…The transmission of hepatiti s B virus from mother to fetus plays an important role in maintaining and spreading this infection (1). The mother is a source of contamination if she is a chronic symptomatic or asymptomatic carrier of hepatitis B antigen (HBsAg) (2)(3)(4)(5)(6). The prevalence of chronic carriers (HBsAg +) varies notably depending on the population and the geographic area (7,8).…”

mentioning

confidence: 99%

See 1 more Smart Citation

Prevention of Perinatally Transmitted Hepatitis B Virus Infection by Hepatitis B Immunoglobulin Immunoprophylaxis

Foschini,

De Toni,

Padula

et al. 1985

J. pediatr. gastroenterol. nutr.

View full text Add to dashboard Cite

SummaryOf 5,327 pregnant women who were screened between July 1981 and July 1983, 5.2% were found to be hepatitis Bs antigen (HBsAg) carriers. This high percentage of carriers accentuates the importance of vertical transmission of hepatitis B virus in our area. In view of this we sought to verify the effectiveness of hyperimmune immunoglobulins in the prevention of infection. We studied 201 babies born to HBsAg‐positive mothers. These babies had regular checkups until 12 months of age. One hundred forty‐nine received prophylactic hyperimmune globulin (two to seven doses according to risk ranking), while 52 did not. A higher percentage of infection was found in the babies who had no prophylaxis (25%) than in the babies who had prophylaxis (7.4%). Furthermore, hepatitis appeared earlier (from the 2nd to the 6th month) in the babies who had no prophylaxis than in the babies who had prophylaxis (from the 9th to the 12th month). No infection was observed during prophylaxis or up to 6 months.

show abstract

“…4, No. 4,1985 Our study was carried out on a considerable number of infants at risk of infection and confirms some data that have already appeared in the literature:…”

Section: Discussionsupporting

confidence: 88%

mentioning

confidence: 99%

Prevention of Perinatally Transmitted Hepatitis B Virus Infection by Hepatitis B Immunoglobulin Immunoprophylaxis

Foschini,

De Toni,

Padula

et al. 1985

J. pediatr. gastroenterol. nutr.

View full text Add to dashboard Cite

show abstract

“…We chose hyaluronic acid (HA) as our biopolymer multi-cross-linker since HA is anionic for promoting fusion of cationic liposomes into multilamellar vesicles, 18 biocompatible, and used widely in FDA-approved products. 19 Here, we demonstrate that MVPs can be stably coloaded with protein antigens and mono-phosphoryl lipid A (MPLA), a Toll-like receptor (TLR) 4 agonist approved for use in vaccine products, 20,21 and that MVPs efficiently activate DCs and promote antigen processing. Using ovalbumin (OVA) as the model antigen, we show that immunizations with MVPs carrying OVA and MPLA induce robust expansion of OVA-specific CD8 + and CD4 + T cells and elicit durable cellular and humoral immune responses in vivo.…”

mentioning

confidence: 99%

Multilamellar Vaccine Particle Elicits Potent Immune Activation with Protein Antigens and Protects Mice against Ebola Virus Infection

Fan

Stronsky

et al. 2019

ACS Nano

View full text Add to dashboard Cite

Recent outbreaks of emerging infectious diseases, such as Ebola virus disease (EVD), highlight the urgent need to develop effective countermeasures, including prophylactic vaccines. Subunit proteins derived from pathogens provide a safe source of antigens for vaccination, but they are often limited by their low immunogenicity. We have developed a multilamellar vaccine particle (MVP) system composed of lipid−hyaluronic acid multi-cross-linked hybrid nanoparticles for vaccination with protein antigens and demonstrate their efficacy against Ebola virus (EBOV) exposure. MVPs efficiently accumulated in dendritic cells and promote antigen processing. Mice immunized with MVPs elicited robust and long-lasting antigen-specific CD8 + and CD4 + T cell immune responses as well as humoral immunity. A single-dose vaccination with MVPs delivering EBOV glycoprotein achieved an 80% protection rate against lethal EBOV infection. These results suggest that MVPs offer a promising platform for improving recombinant protein-based vaccine approaches.

show abstract

Dramatism and Musical Theater

Cited by 2 publications

References 0 publications

Prevention of Perinatally Transmitted Hepatitis B Virus Infection by Hepatitis B Immunoglobulin Immunoprophylaxis

Prevention of Perinatally Transmitted Hepatitis B Virus Infection by Hepatitis B Immunoglobulin Immunoprophylaxis

Multilamellar Vaccine Particle Elicits Potent Immune Activation with Protein Antigens and Protects Mice against Ebola Virus Infection

Contact Info

Product

Resources

About